| scholarly article | Q13442814 |
| P50 | author | Ted M. Dawson | Q56046960 |
| Darren J Moore | Q87693446 | ||
| P2093 | author name string | Valina L Dawson | |
| Xiaojie Li | |||
| Yulan Xiong | |||
| P2860 | cites work | Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity | Q22254785 |
| The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity | Q24297634 | ||
| Kinase activity of mutant LRRK2 mediates neuronal toxicity | Q24303603 | ||
| The familial Parkinsonism gene LRRK2 regulates neurite process morphology | Q24317613 | ||
| The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation | Q24318533 | ||
| Localization of LRRK2 to membranous and vesicular structures in mammalian brain | Q24318643 | ||
| LRRK2 regulates synaptic vesicle endocytosis | Q24336523 | ||
| Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity | Q24338647 | ||
| Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
| Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease | Q28292932 | ||
| Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study | Q29614953 | ||
| LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity | Q29615144 | ||
| Regulation of protein kinases; controlling activity through activation segment conformation | Q29620471 | ||
| Kinase activity is required for the toxic effects of mutant LRRK2/dardarin | Q29620478 | ||
| GTPase activity plays a key role in the pathobiology of LRRK2. | Q33553458 | ||
| Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain | Q33649391 | ||
| Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease | Q33812599 | ||
| CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity | Q37115256 | ||
| Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization | Q37479332 | ||
| Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. | Q37531309 | ||
| The prevalence of the G2019S and R1441C/G/H mutations in LRRK2 in German patients with Parkinson's disease | Q44594403 | ||
| Clinical features of LRRK2-associated Parkinson's disease in central Norway | Q44830290 | ||
| Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients. | Q46355515 | ||
| Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays. | Q54781213 | ||
| LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity. | Q54786905 | ||
| Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation | Q57373779 | ||
| P4510 | describes a project that uses | ImageQuant | Q112270642 |
| P433 | issue | 38 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phosphorylation | Q242736 |
| Parkinson's disease | Q11085 | ||
| P304 | page(s) | 29569-29576 | |
| P577 | publication date | 2010-07-01 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2 | |
| P478 | volume | 285 |
| Q24339094 | 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization |
| Q33985278 | Arsenite stress down-regulates phosphorylation and 14-3-3 binding of leucine-rich repeat kinase 2 (LRRK2), promoting self-association and cellular redistribution |
| Q37249125 | Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease. |
| Q30981887 | Differential regulation of PKD isoforms in oxidative stress conditions through phosphorylation of a conserved Tyr in the P+1 loop |
| Q33945342 | Efficient Allele-Specific Targeting of LRRK2 R1441 Mutations Mediated by RNAi |
| Q39559544 | Functional phosphosite screening for targeted protein–protein interactions by combining phosphoproteomics strategies and mammalian two-hybrid assays |
| Q90375075 | GTP-binding inhibitors increase LRRK2-linked ubiquitination and Lewy body-like inclusions |
| Q21144926 | GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1 |
| Q27013695 | Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications |
| Q38019676 | Kinases and kinase signaling pathways: Potential therapeutic targets in Parkinson's disease |
| Q51082156 | LRRK2 Phosphorylation |
| Q96953324 | LRRK2 Phosphorylation, More Than an Epiphenomenon |
| Q60143544 | LRRK2 activation in idiopathic Parkinson's disease. |
| Q24292798 | LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool |
| Q24306239 | LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: Impairment of the kinase activity by Parkinson's disease-associated mutations |
| Q24300605 | LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status |
| Q48483202 | LRRK2 kinase activity mediates toxic interactions between genetic mutation and oxidative stress in a Drosophila model: Suppression by curcumin |
| Q38218398 | LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis |
| Q34986076 | Models for LRRK2-Linked Parkinsonism |
| Q38071833 | Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease |
| Q46520584 | Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease. |
| Q39164937 | Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models |
| Q37856642 | On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies |
| Q38044439 | Phosphorylation of LRRK2: from kinase to substrate |
| Q38182492 | Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2). |
| Q38798535 | Regulatory roles of conserved phosphorylation sites in the activation T-loop of the MAP kinase ERK1 |
| Q24294458 | Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease |
| Q27681111 | Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations |
| Q45143202 | Structural and functional in silico analysis of LRRK2 missense substitutions |
| Q38213378 | Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation |
| Q47225650 | The LRRK2 signalling system |
| Q35605204 | Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity |
Search more.